Company: NDRA
Filing Date: 2025-11-14
Form Type: 10-Q
Source: 0001213900-25-110887
Chunk: 0

Company: ENDRA Life Sciences Inc.
Filing Date: 2025-11-14
Form: 10-Q
Item: Part I, Item 1
Chunk 0
---
Item 1. Financial Statements

ENDRA Life Sciences Inc.

Condensed Consolidated Balance Sheets

    September 30, 2025  
    December 31, 2024 

    (Unaudited)  

    Assets 

    Current Assets 

    Cash 
    $794,036  
    $3,229,480 
  
    Prepaid expenses 
     254,673  
     204,185 
  
    Total Current Assets 
     1,048,709  
     3,433,665 
  
    Non-Current Assets 

    Fixed assets, net 
     52,633  
     69,281 
  
    Right of use assets 
     491,363  
     578,013 
  
    Prepaid expenses, long term 
     365,417  
     365,417 
  
    Other assets 
     5,986  
     5,986 

    Total Assets 
    $1,964,108  
    $4,452,362 

    Liabilities and Stockholders’ Equity 

    Current Liabilities 

    Accounts payable and accrued liabilities 
    $671,516  
    $508,293 
  
    Lease liabilities, current portion 
     128,791  
     96,937 
  
    Total Current Liabilities 
     800,307  
     605,230 

    Long Term Debt 

    Lease liabilities 
     396,537  
     487,482 
  
    Warrant Liability 
     595,884  
     799,284 
  
    Total Long Term Debt 
     992,421  
     1,286,766 

    Total Liabilities 
     1,792,728  
     1,891,996 

    Stockholders’ Equity 

    Series A Convertible Preferred Stock, $0.0001 par value; 10,000 shares authorized; 17.488 and 17.488 shares issued and outstanding, respectively 
     -  
     - 
  
    Series B Convertible Preferred Stock, $0.0001 par value; 1,000 shares authorized; no shares issued and outstanding 
     -  
     - 
  
    Series C Preferred Stock, $0.0001 par value; 100,000 shares authorized; no shares issued